GleamWall
中文EN

AVXL ANAVEX LIFE SCIENCES CORP.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1314052 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY73.0%
TTM EPS YoY75.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-12.8%
ROA-11.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.25x
Accruals ratio14.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue————————
R&D expense—$4.19M$4.66M$7.29M$9.96M$9.89M$10.45M$11.55M
SG&A expense$2.03M$2.29M$2.13M$3.55M$4.50M$2.62M$3.15M$2.78M
Operating income$6.74M-$6.48M-$6.78M-$10.84M-$14.46M-$12.51M-$13.59M-$14.34M
Pretax income———————-$11.74M
Income tax$0$0$18,000—————
Net income$7.82M-$5.34M-$5.68M-$9.83M-$13.24M-$11.20M-$12.11M-$11.62M
EPS (basic)0.08-0.06-0.06—-0.16-0.13-0.14—
EPS (diluted)0.08-0.06-0.06—-0.16-0.13-0.14—
Weighted avg. shares (diluted)92.90B92.68M89.03M—85.38B85.07M84.81M—
Banking
Net interest income$1.07M$1.06M$1.08M$999,000$1.07M$1.21M$1.39M$1.76M
Balance sheet
Cash & equivalents$118.33M$127.42M$131.75M$102.58M$101.16M$115.77M$120.78M$132.19M
Total assets$120.14M$128.77M$132.99M$103.81M$102.43M$117.14M$124.04M$135.57M
Total liabilities$7.69M$7.06M$6.37M$8.95M$11.47M$17.38M$13.13M$15.30M
Shareholders' equity$112.45M$121.71M$126.62M$94.87M$90.96M$99.76M$110.92M$120.26M
Shares outstanding92.70M92.70M92.67M86.67M85.41M85.33M84.99M84.80M
Cash flow statement
Operating cash flow-$9.10M-$4.44M-$7.15M-$8.60M-$12.46M-$5.86M-$12.12M-$6.66M
Financing cash flow$0$113,000$36.32M$10.02M-$2.14M$852,000$708,000$89,000
Stock-based compensation-$17.08M$314,000$1.11M$3.72M$4.32M$1.45M$2.06M$2.01M

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.